In this context, Yang et al. have already shown that addition of Dactolisib, a dual PI3K/mTOR inhibitor or ZSTK474, a pan-PI3K inhibitor, in combination with Temsirolimus, a mTORC1 inhibitor, synergistically inhibited cancer cell growth and overcame cellular resistance to Temsirolimus regardless of PTEN status [426]. This evidence concerns the gene PIK3CA and cancer.